Physician profile
John Peterson
NPI 1245211242
$14,977.75
in general payments reported to CMS, 2019-2025
80 companies · $4,233 in 2025
The $4,233 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,701 · 2020: $415 · 2021: $132 · 2022: $1,462 · 2023: $2,707 · 2024: $3,328 · 2025: $4,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,136.58 |
| Education | $130.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,209.76 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Novartis Pharmaceuticals Corporation | $1,173.30 | 2019-2025 | Piqray, Kisqali |
| Pfizer INC. | $838.49 | 2019-2025 | |
| Janssen Biotech, INC. | $823.91 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $658.10 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $648.13 | 2020-2025 | Enhertu, Datroway |
| Celgene Corporation | $638.82 | 2019-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $561.26 | 2019-2025 | Opdivo, Krazati, Augtyro |
| Incyte Corporation | $558.63 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Lilly USA, LLC | $514.79 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $437.66 | 2019-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $370.74 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Genentech USA, INC. | $347.59 | 2019-2025 | Tecentriq, Itovebi, Phesgo |
| Glaxosmithkline, LLC. | $286.45 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Jazz Pharmaceuticals INC. | $270.88 | 2022-2023 |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $241.59 | 2019-2025 | |
| Amgen INC. | $237.16 | 2019-2023 | Lumakras |
| Astellas Pharma US INC | $233.78 | 2019-2025 | Xtandi, Xospata, Padcev |
| Genzyme Corporation | $219.33 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $209.00 | 2024-2025 | Libtayo |
| Pharmaessentia USA Corporation | $199.44 | 2023-2025 | Besremi |
| Seagen INC. | $192.22 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Sobi, INC | $191.00 | 2022-2025 | |
| Novocure INC. | $178.59 | 2019 | |
| Array Biopharma INC | $175.48 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Exelixis INC. | $165.16 | 2019-2025 | Cabometyx |
| Dendreon Pharmaceuticals LLC | $157.71 | 2021-2025 | Provenge |
| Abbvie INC. | $150.02 | 2019-2024 | |
| Kite Pharma, INC. | $149.68 | 2022-2023 | Yescarta |
| Kyowa Kirin, INC. | $137.99 | 2019-2022 | |
| Stemline Therapeutics INC. | $137.56 | 2023-2025 | Orserdu |
| Axonics, INC. | $137.14 | 2023 | Axonics |
| Tersera Therapeutics LLC | $135.91 | 2019-2025 | Zoladex |
| Csl Behring | $130.22 | 2022-2025 | Idelvion, Afstyla, Hemgenix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.48 | 2019-2025 | Gilotrif |
| Emd Serono, INC. | $124.82 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $109.34 | 2023-2024 | Monoferric, Cosela |
| Taiho Oncology, INC. | $107.15 | 2024-2025 | |
| Tesaro, INC. | $106.39 | 2019 | |
| Abbott Laboratories | $105.91 | 2025 | Triclip |
| Bayer Healthcare Pharmaceuticals INC. | $100.63 | 2019-2025 | |
| Fennec Pharmaceuticals, INC. | $97.14 | 2024-2025 | Pedmark, Fyarro |
| Puma Biotechnology, INC. | $83.38 | 2019-2025 | |
| Geron Corporation | $81.78 | 2025 | Rytelo |
| Springworks Therapeutics, INC. | $77.48 | 2024-2025 | Ogsiveo |
| Allergan, INC. | $73.83 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $73.37 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $73.07 | 2022-2024 | Xarelto |
| Beigene USA, INC. | $70.89 | 2023-2024 | Brukinsa, Tevimbra |
| Sumitomo Pharma America, INC. | $66.27 | 2023-2025 | Orgovyx |
| Immunocore Limited | $56.07 | 2025 | Kimmtrak |
| G1 Therapeutics, INC. | $54.14 | 2023 | Cosela |
| Genmab U.S., INC. | $53.13 | 2023-2025 | Epkinly |
| Acrotech Biopharma INC. | $43.86 | 2023-2024 | Beleodaq |
| Blueprint Medicines Corporation | $43.11 | 2024-2025 | Ayvakit |
| Novo Nordisk INC | $42.45 | 2023-2024 | Novoseven, Rebinyn, Novoeight |
| Beone Medicines USA, INC. | $38.60 | 2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $31.27 | 2019-2025 | Ultomiris |
| Legend Biotech USA INC. | $30.60 | 2025 | Carvykti |
| Karyopharm Therapeutics INC. | $27.74 | 2025 | Xpovio |
| Iovance Biotherapeutics, INC. | $27.02 | 2025 | Amtagvi |
| Servier Pharmaceuticals LLC | $24.33 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $23.21 | 2019 | |
| Syndax Pharmaceuticals, INC. | $22.28 | 2025 | |
| Adc Therapeutics America, INC. | $20.74 | 2025 | |
| Aurobindo Pharma USA, INC. | $20.00 | 2019 | |
| Aveo Pharmaceuticals, INC. | $19.43 | 2025 | |
| Amag Pharmaceuticals, INC. | $18.43 | 2019 | |
| Global Blood Therapeutics, INC. | $17.69 | 2022 | |
| Ge Healthcare | $17.34 | 2022 | |
| Organon LLC | $16.92 | 2023 | Ontruzant |
| Sun Pharmaceutical Industries INC. | $16.86 | 2025 | |
| Shield Therapeutics INC | $16.84 | 2024 | |
| Clovis Oncology, INC. | $16.54 | 2019 | |
| Progenics Pharmaceuticals, INC. | $15.68 | 2023 | Pylarify |
| Coherus Oncology, INC. | $14.42 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.26 | 2023 | Givlaari |
| Epizyme, INC. | $12.89 | 2022 | |
| Dova Pharmaceuticals | $11.93 | 2019 | |
| Rigel Pharmaceuticals, INC. | $11.55 | 2020 |
Drugs and devices associated with these payments
Enhertu $744Keytruda $479Reblozyl $462Verzenio $341Tukysa $298Kisqali $264Ibrance $252Jakafi $248Trodelvy $222Jaypirca $216Erleada $213Libtayo $209Besremi $199Padcev $193Adcetris $192Darzalex $185Opdivo $183Lutathera $174Tecvayli $171Ninlaro $170Elrexfio $170Monjuvi $165Calquence $155Ojjaara $154Imfinzi $152Zepzelca $149Lynparza $149Braftovi $141Orserdu $138Axonics $137Piqray $136Jemperli $133Zejula $133Doptelet $130Carvykti $126Pluvicto $123Yescarta $122Alunbrig $116Imbruvica $115Talvey $107Inqovi $107Lonsurf $107Triclip $106Cabometyx $99.63Idelvion $94.88Mektovi $92.17Monoferric $91.82Tecentriq $91.29Provenge $90.98Lenvima $88.10Orgovyx $86.70Keytruda Qlex $85.41Xtandi $83.27Zynyz $82.03Rytelo $81.78Afstyla $81.67Retevmo $80.10Rybrevant $77.13Brukinsa $75.88Lorbrena $74.39Pedmark $72.75Welireg $72.22Cosela $71.66Fruzaqla $67.58Enjaymo $64.00Xarelto $58.95Sarclisa $57.30Kimmtrak $56.07Epkinly $53.13Ogsiveo $52.36Scemblix $51.75Venclexta $48.22Krazati $47.58Mekinist $43.86Beleodaq $43.86Vonjo $43.32Augtyro $43.12Ayvakit $43.11Inlyta $42.64Novoseven $42.45Rebinyn $42.45Novoeight $42.45Opdualag $41.97Bosulif $41.70Pomalyst $41.58Akeega $40.25Itovebi $38.93Xospata $37.42Zoladex $37.41Vitrakvi $33.73Nubeqa $33.73Stivarga $33.73Tevimbra $33.61Phesgo $33.33Wayrilz $31.23Xpovio $27.74Amtagvi $27.02Tabrecta $26.36Pemazyre $25.24Datroway $24.78
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.